Laure Stiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Laure Stiel has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Agathe Debliquis
Laboratoire d’Hématologie, Groupe Hospitalier de la Région Mulhouse Sud Alsace, Mulhouse, France
1 shared publication- Agathe Debliquis
Laboratoire d'hématologie Groupe Hospitalier de la région Mulhouse Sud Alsace Mulhouse France
1 shared publication Alexandre Gaudet
CHU Lille, Department of Intensive Care Medicine, Critical Care Center, Univ. Lille, Lille, France
1 shared publication- Anne-Astrid Bourion
Réanimation, Centre Hospitalier de Cholet, Cholet, France
1 shared publication Anne‐Florence Dureau
Service de Réanimation Médicale Groupe Hospitalier de la Région Mulhouse Sud Alsace Mulhouse France
1 shared publication- Arnaud Wilfrid Thille
Service de Médecine Intensive Réanimation, CHU de Poitiers, Poitiers, France
1 shared publication
Latest Publications
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
L’activation des polynucléaires neutrophiles au cours du choc septique
Ce travail visait à étudier l’activation des polynucléaires neutrophiles (PNNs) au cours du choc septique. Après une introduction sur la physiopathologie du choc septique, de la coagulation intravasculaire disséminée (CIVD) et des PNNs, nous rapportons différents résultats expérimentaux et cliniques. Dans une étude prospective sur 100 patients, nous avons montré que l’activation des PNNs, mesurée par leur fluorescence en cytométrie en flux pourrait représenter un marqueur diagnostique original de la CIVD du choc septique. Ensuite, nous avons mis en évidence un des mécanismes de l’activation des PNNs, la NETose, à l’aide de marqueurs sériques. Afin de confirmer la relevance de ce phénomène, nous avons visualisé les NETs spécifiquement dans le sang de patients en choc septique avec CIVD en immunofluorescence. Enfin, nous avons identifié des protéines associées à l’activation du PNN dans la CIVD du choc septique par une étude protéomique, afin d’en envisager les mécanismes. Le PNN pourrait ainsi être un acteur incontournable de la dérégulation de l’immunothrombose au cours de la CIVD, et être envisagé comme cible thérapeutique.
- 4 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
L’activation des polynucléaires neutrophiles au cours du choc septique
Ce travail visait à étudier l’activation des polynucléaires neutrophiles (PNNs) au cours du choc septique. Après une introduction sur la physiopathologie du choc septique, de la coagulation intravasculaire disséminée (CIVD) et des PNNs, nous rapportons différents résultats expérimentaux et cliniques. Dans une étude prospective sur 100 patients, nous avons montré que l’activation des PNNs, mesurée par leur fluorescence en cytométrie en flux pourrait représenter un marqueur diagnostique original de la CIVD du choc septique. Ensuite, nous avons mis en évidence un des mécanismes de l’activation des PNNs, la NETose, à l’aide de marqueurs sériques. Afin de confirmer la relevance de ce phénomène, nous avons visualisé les NETs spécifiquement dans le sang de patients en choc septique avec CIVD en immunofluorescence. Enfin, nous avons identifié des protéines associées à l’activation du PNN dans la CIVD du choc septique par une étude protéomique, afin d’en envisager les mécanismes. Le PNN pourrait ainsi être un acteur incontournable de la dérégulation de l’immunothrombose au cours de la CIVD, et être envisagé comme cible thérapeutique.
- Open Access
- 3 September 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 137-16
Innate immune response in acute critical illness: a narrative review
- 3 September 2024
- Published by Elsevier in Annals of Intensive Care
- Vol. 14 (1) , 137-16
Open AccessInnate immune response in acute critical illness: a narrative review
- Open Access
- 17 June 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 53-13
Insulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units
- 17 June 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 53-13
Open AccessInsulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units
- Open Access
- 17 November 2021
- Published by Hindawi Limited in Disease Markers
- Vol. 2021, 1-8
NEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus first identified in December 2019 in Wuhan, China, and responsible for coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic is impacting healthcare worldwide. Patients who develop coagulopathy have worse outcomes. The pathophysiology of COVID-19 suggests a strong interplay between hemostasis and immune cells, especially neutrophils. Our purpose was to assess neutrophil fluorescence as a potential biomarker of deep vein thrombosis (DVT) in patients with COVID-acute respiratory distress syndrome (COVID-ARDS). Sixty-one patients with COVID-ARDS admitted to the four intensive care units (ICUs) of a French general hospital were included in this prospective study. Neutrophil activation was assessed by measuring neutrophil fluorescence (NEUT-Side Fluorescence Light, NEUT-SFL) with a specific fluorescent dye staining analyzed by a routine automated flow cytometer Sysmex XN-3000™ (Sysmex, Kobe, Japan). DVT was diagnosed by complete duplex ultrasound (CDU). We found that NEUT-SFL was elevated on admission in patients with COVID-ARDS (49.76 AU, reference value 46.40 AU, p < 0.001 ), but did not differ between patients with DVT (49.99 AU) and those without (49.52 AU, p = 0.555 ). NEUT-SFL is elevated in patients with COVID-ARDS, reflecting neutrophil activation, but cannot be used as a marker of thrombosis. Because neutrophils are at interface between immune response and hemostasis through release of neutrophil extracellular traps, monitoring their activation could be an interesting approach to improve our management of coagulopathy during COVID-ARDS. Further research is needed to better understand the pathophysiology of COVID-19 and identify high-performance biomarkers.
- 17 November 2021
- Published by Hindawi Limited in Disease Markers
- Vol. 2021, 1-8
Open AccessNEUT-SFL in Patients with COVID-ARDS: A Novel Biomarker for Thrombotic Events?
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA virus first identified in December 2019 in Wuhan, China, and responsible for coronavirus disease 2019 (COVID-19). The ongoing COVID-19 pandemic is impacting healthcare worldwide. Patients who develop coagulopathy have worse outcomes. The pathophysiology of COVID-19 suggests a strong interplay between hemostasis and immune cells, especially neutrophils. Our purpose was to assess neutrophil fluorescence as a potential biomarker of deep vein thrombosis (DVT) in patients with COVID-acute respiratory distress syndrome (COVID-ARDS). Sixty-one patients with COVID-ARDS admitted to the four intensive care units (ICUs) of a French general hospital were included in this prospective study. Neutrophil activation was assessed by measuring neutrophil fluorescence (NEUT-Side Fluorescence Light, NEUT-SFL) with a specific fluorescent dye staining analyzed by a routine automated flow cytometer Sysmex XN-3000™ (Sysmex, Kobe, Japan). DVT was diagnosed by complete duplex ultrasound (CDU). We found that NEUT-SFL was elevated on admission in patients with COVID-ARDS (49.76 AU, reference value 46.40 AU, p < 0.001 ), but did not differ between patients with DVT (49.99 AU) and those without (49.52 AU, p = 0.555 ). NEUT-SFL is elevated in patients with COVID-ARDS, reflecting neutrophil activation, but cannot be used as a marker of thrombosis. Because neutrophils are at interface between immune response and hemostasis through release of neutrophil extracellular traps, monitoring their activation could be an interesting approach to improve our management of coagulopathy during COVID-ARDS. Further research is needed to better understand the pathophysiology of COVID-19 and identify high-performance biomarkers.
- Open Access
- 2 May 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (1) , 8
Intracellular hypervirulent Klebsiella pneumoniae in the bone marrow aspirate of a patient with multiple site infection
- 2 May 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (1) , 8
Open AccessIntracellular hypervirulent Klebsiella pneumoniae in the bone marrow aspirate of a patient with multiple site infection
- Open Access
- 1 November 2019
- Published by Elsevier in Thrombosis Research
- Vol. 183, 153-158
First visualization of circulating neutrophil extracellular traps using cell fluorescence during human septic shock-induced disseminated intravascular coagulation
- 1 November 2019
- Published by Elsevier in Thrombosis Research
- Vol. 183, 153-158
Open AccessFirst visualization of circulating neutrophil extracellular traps using cell fluorescence during human septic shock-induced disseminated intravascular coagulation